Bio-Works secures another order from PolyPeptide
February 27, 2018 / erik abrahamsson
Press release Februari 23 2018
Bio-Works has received an order of 1,0 million SEK from PolyPeptide. During 2017 Bio-Works received four orders from PolyPeptide, which is one of the largest contract manufacturers in the world for peptide pharmaceuticals. They have 25 % of the global market for contract manufacturing of peptide pharmaceuticals. This order will be delivered during the first quarter of 2018.
Mats Johnson, Bio-Works CEO:
”The high frequency of orders from PolyPeptide shows their trust in that Bio-Works’ products will give them the optimal productivity in scale-up and in their transition to industrial production. We are very happy for the trust PolyPeptide once again shows us in ordering our products. We look forward to a continued good collaboration.
Bio-Works’ historical sales figures represent the earlier phases of our customers’ scale-up processes, which is the development phase before industrial production. In industrial production each project a customer is running, can be worth up to 10 million SEK in yearly revenue for Bio-Works. At the 105 customers Bio-Works have today, approx. 10 projects are at the end of the scale-up phase, the last stage before industrial production. We expect for that several of our customers’ scale-up projects will move into production during this year.”
For more information please visit Bio-Works’ homepage, www.bio-works.com, or contact Mats Johnson, CEO for Bio-Works, e-mail: firstname.lastname@example.org, telephone: +46 70 516 53 37.
Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose based high performance products are used for purificationin the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.